MLLT3 and acute myeloid leukemia: To understand the impact of BRD9 loss on chromatin accessibility in primary AML cells, we performed ATAC-seq 10 days after pIpC injection in MLL-AF9 transformed bone marrow cells from Mx1-cre Brd9fl/fl mice.